Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06013995 · ClinicalTrials.gov registry record · Phase 1

A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus

A Phase 1 study of Lupus, sponsored by Bristol-Myers Squibb.

Recruiting
Registry status
Phase 1
Development phase
44
Enrollment target
20
Study locations

NCT06013995 is a Phase 1 study of Lupus that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 44 participants, below the 282-participant average among 13 other Lupus trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06013995, a Phase 1 study of Lupus, is actively recruiting participants, sponsored by Bristol-Myers Squibb.

RECRUITING
Registry status
Phase 1
Development phase
44 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.

Conditions Studied

Lupus

Interventions

  • DRUG BMS-986326
  • OTHER Placebo for BMS-986326

Study Locations (20)

Other

  • Local Institution - 0072 - Sofia
  • Local Institution - 0044 - Berlin
  • Local Institution - 0071 - Dessau
  • Local Institution - 0047 - Dresden
  • Local Institution - 0077 - Chihuahua City

Florida

  • Clinical Research of West Florida, Inc. (Clearwater) - Clearwater
  • Clinical Research of West Florida - Tampa

Texas

  • Allen Arthritis - Allen
  • Metroplex Clinical Research Center - Dallas

DIF

  • Local Institution - 0073 - Cuauhtémoc, Ciudad de México
  • Local Institution - 0068 - Mexico City

California

  • Local Institution - 0048 - San Diego

Georgia

  • North Georgia Rheumatology - Lawrenceville

Kentucky

  • Skin Sciences - Louisville

Nevada

  • Local Institution - 0062 - Las Vegas

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2023-09-21
Est. Completion 2026-04-12
Phase Phase 1

Sponsor

Bristol-Myers Squibb

1,025 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06013995

The ClinicalTrials.gov registry entry for NCT06013995 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 13 other Lupus trials with a reported enrollment target (84% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lupus appearing as the primary indexed condition, and to 2 interventions - of which BMS-986326 is the first listed.

NCT06013995 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Florida, Texas.

Frequently Asked Questions

What is clinical trial NCT06013995 about?

NCT06013995 is a clinical study titled "A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus". The purpose of this study is to evaluate safety, drug levels and drug effects on cells and organs of the body, after receiving multiple increasing doses of BMS-986326 via intravenous (IV) infusion or subcutaneous (SC) injection, in participants with different forms of lupus.

What is the current status of trial NCT06013995?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2023-09-21. Estimated completion is 2026-04-12.

What conditions does trial NCT06013995 study?

This clinical trial studies the following conditions: Lupus.

What interventions are being tested in trial NCT06013995?

The interventions under investigation include: BMS-986326 (DRUG), Placebo for BMS-986326 (OTHER).

Who is sponsoring clinical trial NCT06013995?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06013995 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Kentucky, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lupus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lupus

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.